BMEA (Biomea Fusion) Ending Cash Position: $35.19 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMEA Biomea Fusion Inc BMEA
33 GF Score
Price $1.29
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion Ending Cash Position?

Biomea Fusion BMEA +0.79% 33 Ending Cash Position is $35.19 Mil as of Jun. 2026. GuruFocus rates BMEA with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Biomea Fusion's Ending Cash Position for the quarter that ended in Jun. 2026 was $35.19 Mil.

Biomea Fusion's quarterly Ending Cash Position declined from Dec. 2025 ($56.18 Mil) to Mar. 2026 ($45.06 Mil) and declined from Mar. 2026 ($45.06 Mil) to Jun. 2026 ($35.19 Mil).

Biomea Fusion's annual Ending Cash Position declined from Dec. 2023 ($177.24 Mil) to Dec. 2024 ($58.65 Mil) and declined from Dec. 2024 ($58.65 Mil) to Dec. 2025 ($56.18 Mil).

Biomea Fusion Ending Cash Position Related Terms

Biomea Fusion Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Biomea Fusion's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomea Fusion Ending Cash Position Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 146.09 112.25 177.24 58.65 56.18

Biomea Fusion Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.59 47.01 56.18 45.06 35.19
BMEA
33GF Score
Biomea Fusion Inc BMEA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomea Fusion Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Biomea Fusion's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=58.648+-2.467
=56.18

Biomea Fusion's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=45.062+-9.869
=35.19

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $35.19 Mil mean?
Biomea Fusion (BMEA) has a Ending Cash Position of $35.19 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Biomea Fusion and its competitors.
Is Biomea Fusion's Ending Cash Position too high?
Biomea Fusion's current Ending Cash Position is $35.19 Mil. Overall, Biomea Fusion has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's Ending Cash Position compare to NTHI and PTHS?
Biomea Fusion's Ending Cash Position of $35.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Biomea Fusion and its competitors. Biomea Fusion's current Ending Cash Position is $35.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current Ending Cash Position of $35.19 Mil. The current Ending Cash Position is $35.19 Mil. Biomea Fusion's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current Ending Cash Position is $35.19 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
33GF Score

Get the complete analysis for BMEA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.29
Price